Frequently Asked Questions

About AntibodyLLM

What is AntibodyLLM?

AntibodyLLM is an AI-powered antibody engineering and contract research/manufacturing platform founded in 2020 and commercially launched in 2024. Headquartered in Houston, TX, the platform combines large language model (LLM)-based antibody design with a proprietary deterministic CHO cell expression system to deliver faster, higher-yield antibody development.

How does AI improve antibody engineering?

AI improves antibody engineering by predicting sequence-structure-function relationships before wet-lab experiments. AntibodyLLM's platform uses large language models to design antibody sequences optimized for affinity, stability, and expressibility — enabling generative design of novel sequences and multi-objective optimization. This reduces failed experiments and compresses development timelines by up to 50% compared to traditional iterative approaches.

Technology

What is CRISPR site-specific integration and why does it matter?

CRISPR site-specific integration inserts the gene of interest into a predetermined, transcriptionally active location in the host cell genome. Unlike random integration, this eliminates positional variability — the leading cause of clone-to-clone inconsistency in traditional cell line development. AntibodyLLM's CRISPR platform delivers consistent high expression levels without screening hundreds of clones.

What is UCOE and how does it prevent gene silencing?

UCOE (Ubiquitous Chromatin Opening Element) is a DNA element derived from human housekeeping gene promoters that maintains an open chromatin configuration around the integrated transgene. In stable CHO cell lines, UCOE prevents epigenetic silencing (methylation-mediated gene inactivation) that can occur during long-term culture — ensuring sustained high expression levels for 50+ generations.

How long does stable CHO cell line development take?

AntibodyLLM's CRISPR + UCOE platform delivers stable, high-yield CHO cell lines in 10–12 weeks. In fast-track cases, delivery has been achieved in as little as 8 weeks — approximately 50% faster than the industry-standard 16–20 week timeline.

What expression yields can AntibodyLLM achieve?

AntibodyLLM has demonstrated yields of 3.2 g/L (a 3× / 220% improvement over baseline 1.0 g/L) for IgG antibodies. Production scales from transient expression (μg–mg, 1–2 weeks) through large-scale bioreactors (10L–1000L).

Services

What types of antibodies and proteins can AntibodyLLM produce?

AntibodyLLM can produce: monoclonal antibodies (mAbs), bispecific antibodies, antibody fragments (Fab, scFv, nanobodies), Fc-fusion proteins, enzymes, cytokines, growth factors, and recombinant antigens for diagnostic and therapeutic applications.

Does AntibodyLLM offer bispecific antibody development?

Yes. AntibodyLLM offers full bispecific antibody development including AI-guided construct design (knobs-into-holes, CrossMab, and other formats), chain pairing optimization, expression optimization, and purification strategy development. The AI platform specifically addresses the chain mispairing and reduced yield challenges common in bispecific production.

What is AntibodyLLM's project success rate?

AntibodyLLM reports a 95%+ project success rate, compared to an industry average where 30–50% of traditional antibody projects fail or require significant re-work.

Does AntibodyLLM offer contract manufacturing (CMO/OEM/ODM)?

Yes. AntibodyLLM offers OEM and ODM contract manufacturing for both diagnostic and therapeutic antibody applications, from mg-scale research batches to kg-scale commercial production.

How do I start a project with AntibodyLLM?

Submit your sequence, target description, or project requirements via our contact form. The team will review your project and provide a custom proposal and timeline.